Lv71
4950 积分 2023-02-07 加入
CD3 bispecific antibody–induced cytokine release is dispensable for cytotoxic T cell activity
21天前
已完结
Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype
3个月前
已完结
Discussion on the Relationship and Influence Factors of the Limit of Detection and the Sensitivity of Analytical Methods
3个月前
已完结
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies
5个月前
已完结
Advances in the treatment of systemic lupus erythematosus
5个月前
已完结
Elranatamab: a new promising BispAb in multiple myeloma treatment
5个月前
已完结
Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab
5个月前
已完结
A role for STEAP2 in prostate cancer progression
6个月前
已完结
Reducing affinity as a strategy to boost immunomodulatory antibody agonism
6个月前
已完结
A phase I/II study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer: Trial in progress update
6个月前
已完结
皖公网安备34019202002308
